← Browse by Condition
Medical Condition

head and neck squamous cell carcinoma

Total Trials
28
Recruiting Now
28
Trial Phases
Phase 3, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for head and neck squamous cell carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — head and neck squamous cell carcinoma Clinical Trials

How many clinical trials are currently recruiting for head and neck squamous cell carcinoma?
ClinicalMetric currently tracks 28 actively recruiting clinical trials for head and neck squamous cell carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 28. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for head and neck squamous cell carcinoma?
head and neck squamous cell carcinoma research spans Phase 1 (9 trials), Phase 2 (13 trials), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a head and neck squamous cell carcinoma clinical trial?
Eligibility criteria for head and neck squamous cell carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
9
Phase 2
13
Phase 3
2
Top Sponsors
West China Hospital 3 trials
Beijing Tongren Hospital 2 trials
National Cancer Institute, Naples 1 trial
Bicara Therapeutics 1 trial
Nurix Therapeutics, Inc. 1 trial

Recruiting Clinical Trials

NCT06102395 Phase 3
Recruiting
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
Enrollment
272 pts
Location
China
Sponsor
Beijing Tongren Hospital
View Trial →
NCT06905145
Recruiting
Molecular-Based Selection of Patients with Head and Neck Squamous Cell Carcinoma: Biomarker Analysis
Enrollment
128 pts
Location
Italy
Sponsor
National Cancer Institute, Nap...
View Trial →
NCT04429542 Phase 1
Recruiting
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Enrollment
473 pts
Location
United States, Austr...
Sponsor
Bicara Therapeutics
View Trial →
NCT05107674 Phase 1
Recruiting
A Study of NX-1607 in Adults With Advanced Malignancies
Enrollment
345 pts
Location
United States, Unite...
Sponsor
Nurix Therapeutics, Inc.
View Trial →
NCT06022029 Phase 1
Recruiting
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
Enrollment
168 pts
Location
United States, Austr...
Sponsor
OncoNano Medicine, Inc.
View Trial →
NCT07462377 Phase 1
Recruiting
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Enrollment
110 pts
Location
United States, South...
Sponsor
EpiBiologics
View Trial →
NCT06170710 Phase 2
Recruiting
Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC
Enrollment
173 pts
Location
China
Sponsor
Cancer Institute and Hospital,...
View Trial →
NCT06100497 Phase 2
Recruiting
Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC
Enrollment
100 pts
Location
China
Sponsor
Beijing Tongren Hospital
View Trial →
NCT06662058
Recruiting
Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Enrollment
118 pts
Location
United States
Sponsor
Emory University
View Trial →
NCT04807140 Phase 2
Recruiting
Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)
Enrollment
57 pts
Location
China
Sponsor
Sun Yat-Sen Memorial Hospital ...
View Trial →
NCT07567235 Phase 1
Recruiting
Clinical Study of CFH Protein Via Ice Microneedles for Radiation-Induced Skin Fibrosis
Enrollment
9 pts
Location
China
Sponsor
West China Hospital
View Trial →
NCT04564989
Recruiting
Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
Enrollment
220 pts
Location
United States
Sponsor
UNC Lineberger Comprehensive C...
View Trial →
NCT05854823
Recruiting
The Efficacy and Safety of De-escalated Postoperative Radiotherapy in Locally Advanced HNSCC With pCR/MPR
Enrollment
23 pts
Location
China
Sponsor
Fifth Affiliated Hospital, Sun...
View Trial →
NCT05919290
Recruiting
HN-QUEST: A Study of Head and Neck Imaging Biomarkers
Enrollment
173 pts
Location
Canada
Sponsor
University Health Network, Tor...
View Trial →
NCT07825597 Phase 2
Recruiting
Indocyanine Green With Near Infrared Imaging for Intraoperative Visualization of Head and Neck Squamous Cell Carcinoma
Enrollment
25 pts
Location
United States
Sponsor
Washington University School o...
View Trial →
NCT05674396 Phase 2
Recruiting
3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial
Enrollment
108 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT06084481 Phase 1
Recruiting
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Enrollment
325 pts
Location
United States, Austr...
Sponsor
AbbVie
View Trial →
NCT05576974 Phase 2
Recruiting
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
Enrollment
120 pts
Location
United States
Sponsor
University of Texas Southweste...
View Trial →
NCT06248996 Phase 3
Recruiting
a Multicentre Phase III Study of Risk-based Treatment Intensification With Hyperfractionated Radiotherapy in Head and Neck Cancer Patients
Enrollment
308 pts
Location
Sweden
Sponsor
Lund University Hospital
View Trial →
NCT07381075 Phase 2
Recruiting
A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Enrollment
90 pts
Location
China
Sponsor
West China Hospital
View Trial →
NCT06465069 Phase 1
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Enrollment
460 pts
Location
United States, Austr...
Sponsor
Eli Lilly and Company
View Trial →
NCT07572864 Phase 2
Recruiting
Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC
Enrollment
9 pts
Location
China
Sponsor
West China Hospital
View Trial →
NCT06980038 Phase 2
Recruiting
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Enrollment
44 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT05726370 Phase 2
Recruiting
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
Enrollment
28 pts
Location
United States
Sponsor
Dana-Farber Cancer Institute
View Trial →
NCT07105592 Phase 1, Phase 2
Recruiting
A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma
Enrollment
68 pts
Location
China
Sponsor
Fudan University
View Trial →
NCT06422403 Phase 2
Recruiting
A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
Enrollment
360 pts
Location
Singapore
Sponsor
National University Hospital, ...
View Trial →
NCT05996432 EARLY_Phase 1
Recruiting
Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy
Enrollment
48 pts
Location
United States
Sponsor
Vanderbilt-Ingram Cancer Cente...
View Trial →
NCT06007729 Phase 2
Recruiting
ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Enrollment
170 pts
Location
China
Sponsor
Hansoh BioMedical R&D Company
View Trial →

Related Conditions

triple negative breast cancer (3) non small cell lung cancer (3) head and neck cancer (3) oropharyngeal squamous cell carcinoma (3) recurrent head and neck squamous cell carcinoma (3) carcinoma squamous cell (2) cervical cancer (2) bladder cancer (2) hypopharyngeal squamous cell carcinoma (2) laryngeal squamous cell carcinoma (2) oral cavity squamous cell carcinoma (2) recurrent hypopharyngeal squamous cell carcinoma (2)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology